What is IGF-1 LR3? A Research Guide.

LR3IGF-I is an engineered insulin-like growth factor-I analogue, commonly described as having an N-terminal extension and an arginine substitution at position 3. Its modifications mean native IGF-I data cannot automatically be assigned to LR3.[1]

IGF-binding proteins influence how an IGF analogue is carried, cleared and available to interact with cells. The 1993 comparison found that weaker binding by LR3IGF-I coincided with greater potency in the tested cell and rat systems but faster plasma removal. This is more nuanced than saying the analogue is simply “longer lasting.” Binding, biological activity and clearance are different measurements, and a change in one does not predict every outcome in another species.[1][2]

The primary study compares IGFs and analogues in relation to binding proteins, plasma clearance and biological activity in experimental systems. It reports different binding behaviour for LR3IGF-I and native IGF-I.[1]

The 1993 study combined cultured L6 myoblast experiments with rat growth and clearance measurements. LR3IGF-I interacted less with several binding proteins and was removed from rat plasma more rapidly than native IGF-I. The 1994 paper compared plasma from rats, sheep, pigs, humans and chickens and found marked species differences. Even human plasma in a binding assay is not a human intervention trial: it characterizes laboratory behaviour, not clinical effects or safety.[1][2]

A further comparative paper examines binding proteins from several species. Species differences are an important limit: activity or clearance observed in rat experiments cannot simply be assumed to apply in humans.[1][2]

These sources do not establish human muscle-growth benefits or long-term safety for LR3. Evidence concerning other IGF-I preparations or prescribed medicines is not product-specific evidence for this research listing.

Growth-related signalling requires caution when interpreting changes in tissue or cell proliferation. The cited experiments do not establish clinical muscle-growth benefits, long-term safety or an appropriate human exposure. They also show why claims about duration or potency must specify the assay and species rather than being generalized to the product listing.[1][2]